Article

Cancer-Type Specific Prognostic Impact of Concurrent TP53 and KRAS Alterations: A Multi-Cohort Genomic Analysis

2026-03-30

Abstract excerpt

<h4>Background</h4> The tumor suppressor gene TP53 and the oncogene KRAS are among the most frequently altered core drivers in human malignancies. Although they cooperatively regulate critical biological processes, the prognostic impact of their co-alterations remains poorly defined and exhibits striking inconsistency across different cancer types. <h4>Methods</h4> We comprehensively analyzed genomic and clin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e134369c-9d5d-5a56-b80c-41933ea3734b
DOI: 10.64898/2026.03.29.26349383

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cancer-Type Specific Prognostic Impact of Concurrent TP53 and KRAS Alterations: A Multi-Cohort Genomic AnalysisDOI 10.64898/2026.03.29.26349383Read

Comprehensive Analysis of Co-Mutations Identifies Cooperating Mechanisms of TumorigenesisSemantic proximity Read

Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.Semantic proximity Read

Molecular Landscape of TP53/RB1 Co-Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities.Semantic proximity Read

A Pan-Cancer Assessment of RB1/TP53 Co-MutationsSemantic proximity Read

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumorsSemantic proximity Read

Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery.Semantic proximity Read

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma.Semantic proximity Read

Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.Semantic proximity Read

Characterizing genomic differences of human cancer stratified by the TP53 mutation status.Semantic proximity Read

Integrative Multiomic and Deep Learning Profiling of KRAS Mutant and Wildtype Genomes in Pancreatic TumorigenesisSemantic proximity Read

Decoding the Most Mutated Genes in Cancer: a Pan-cancer in Silico Analysis of DLBC, CHOL, UCSSemantic proximity Read

Genomic alterations predictive of poor clinical outcomes in pan-cancer.Semantic proximity Read